Table 3 Characteristics of patients responding and not responding to nivolumab treatment according to iPERCIST
iPERCIST responders (n = 19) | iPERCIST non-responders (n = 9) | p value | |
|---|---|---|---|
Male (%) | 13 (68) | 4 (44) | 0.6775 |
Tobacco use (%) | 16 (84) | 7 (78) | 0.99 |
Age (mean, range), years | 64 (42–79) | 58 (50–79) | 0.22 |
Adenocarcinoma (%) | 14 (74) | 7 (78) | 0.99 |
Lines of chemotherapy before nivolumab (mean, range) | 1.8 (1–5) | 2.0 (1–5) | 0.35 |
Survival (months, median) | 19.9 | 3.6 | < 0.0001 |